Alan Horsager work email
- Valid
- Valid
- Valid
- Valid
Alan Horsager personal email
- Valid
Alan Horsager phone numbers
Alan Horsager, Ph.D. is a life science executive developing genetic medicines for human diseases. His career has been dedicated to early-stage development, translating cutting-edge technologies from academic labs to clinical applications. Dr. Horsager currently serves as the President, CEO, and Director of Duet BioTherapeutics and the President, Immuno-Oncology of Scopus BioPharma.At Duet BioTherapeutics, Dr. Horsager leads the effort to develop targeted bifunctional immunotherapies designed to combat treatment-resistant cancers. These groundbreaking immunotherapies reprogram immune cells within the tumor microenvironment, reinvigorating the immune system's natural cancer-fighting capabilities. Areas of expertise: Immuno-Oncology | Epigenetics | Ophthalmology | Neuroscience | Biotechnology | Therapeutics | Leadership | Management | Strategic Partnerships | Gene Therapy | Optogenetics | Translational Research | Commercialization | Entrepreneurship | Business Development & Strategy | Collaborative Networks | Start-ups
-
Managing PartnerConcept Bio Jun 2024 - PresentConcept Bio is a biotech venture studio offering a unique combination of company building and strategic advisory designed to transform early- and mid-stage ventures into fully realized biotech companies.
-
President & CeoDuet Biotherapeutics Jun 2021 - Jun 2024Los Angeles, Ca, Us -
DirectorDuet Biotherapeutics Jun 2019 - Jun 2024Los Angeles, Ca, UsDuet BioTherapeutics is developing targeted bifunctional immunotherapies to recognize and destroy treatment-resistant cancers. Duet’s immunotherapies reprogram tumor-resident immune cells by activating the TLR9 receptor and suppressing the STAT3 transcription factor. This bifunctional and immune cell-targeted effect restores the immune system's full cancer-killing ability while simultaneously dismantling the immunosuppressive, protective barrier around the tumor.Duet expects to file an IND for DUET-101 in advanced solid tumors in Q3 2024, based on substantial preclinical data in models of prostate, ovarian, head and neck, bladder, and renal cancers, with a Phase 1/2 clinical trial anticipated to begin in Q4 2024 in the United States.
-
ConsultantL.E.K. Consulting Jan 2019 - May 2019Boston, Ma, UsContract with L.E.K. Consulting, a premier strategy consulting firm to the life sciences industry, where I focused primarily on oncology diagnostics. Our clients include four of the top five global biotechnology companies, nine of the top 10 global pharmaceutical companies, leading genomics tools and diagnostics companies, and many of the most innovative emerging public and private companies in the industry. -
President, Ceo, And Co-FounderEpisona Aug 2013 - Dec 2018Pasadena, Ca, UsLead a team of 20+ FTEs, consultants, and collaborators to develop and commercialize a novel epigenetic-based molecular diagnostic test for infertility. Established the viability of the test through multi-center trials for proof-of-concept, clinical utility, and technical validation studies. Raised over $4,500,000 in private investment and negotiated the licenses for university technologies. Built relationships with academic partners, commercial laboratories, and suppliers to allow Episona to focus on its core competency (data analytics and algorithm development) and maintain a lean, flexible organization. Episona’s test was sold internationally through 80+ in-vitro fertility clinics and direct-to-consumer (DTC). 80% of clinic volume was repeat orders from the same clinics. -
Research Assistant ProfessorUniversity Of Southern California May 2009 - Jun 2013Los Angeles, Ca, Us• Led a gene therapy and vision science laboratory focused on the development of optogenetic-based gene therapies for blindness and improving our understanding of the molecular mechanisms underlying retinal degenerative diseases. • Developed strong collaborations with scientific investigators, including USC, University of Florida, and MIT, highlighting my experience in leading cross-functional and interdisciplinary teams.• Raised over $2 million in grants and career awards, including the Coulter Foundation Translational Research Award, and The Burroughs Wellcome Fund CASI Award.• Published 4 scientific papers and invented 2 issued patents. -
Ph.D. CandidateUniversity Of Southern California Aug 2004 - Apr 2009Los Angeles, Ca, Us• Supported the development of a microelectronic retinal prosthesis for blind human patients by creating computational models and algorithms of visual processing, culminating in a market-approved medical device in the United States and Europe.• Collaborated with Second Sight Medical Products (Nasdaq:EYES), demonstrating early involvement in innovative healthcare technologies and partnerships. Second Sight merged with Vivani Medical (Nasdaq:VANI) in 2022.• Published 6 peer-reviewed scientific publications and invented 13 patents granted by the USPTO, showcasing my ability to innovate and create original science.
-
Data Analyst & Clinical Project ManagerVivometrics, Inc. Aug 2001 - Jul 2004Us• Developed computational models and algorithms for a Class II noninvasive ambulatory monitory device, contributing to my technical and analytical competencies. Technology is now being commercialized by VivoSense, Inc.• Lead multiple projects involving Phase I and Phase IV clinical trials with top-tier pharmaceutical companies, showcasing project management skills.
Alan Horsager Skills
Alan Horsager Education Details
-
University Of Southern CaliforniaNeuroscience -
University Of WashingtonPsychology
-
Harvard Medical SchoolHmx Program – Certificate Of Achievment In Immunology
Frequently Asked Questions about Alan Horsager
What company does Alan Horsager work for?
Alan Horsager works for Concept Bio
What is Alan Horsager's role at the current company?
Alan Horsager's current role is Biotech Company Builder & Strategic Advisor.
What is Alan Horsager's email address?
Alan Horsager's email address is ho****@****usc.edu
What is Alan Horsager's direct phone number?
Alan Horsager's direct phone number is +131086*****
What schools did Alan Horsager attend?
Alan Horsager attended University Of Southern California, University Of Washington, Harvard Medical School.
What are some of Alan Horsager's interests?
Alan Horsager has interest in Biotechnology, Health Care Information Technology, Genetic Testing, Diagnostics.
What skills is Alan Horsager known for?
Alan Horsager has skills like Neuroscience, Biotechnology, Medical Devices, Start Ups, Entrepreneurship, Lifesciences, Commercialization, Strategic Partnerships, Business Strategy.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial